Web Exclusives

ASCO guidelines cite significant improvement in progression-free survival when PARP inhibitors are used as maintenance therapy or in the setting of recurrent disease in women with advanced ovarian cancer who have responded to platinum-based chemotherapy in the first line. Read Article ›

In an analysis of the phase 3 PRIMA study, niraparib monotherapy as first-line maintenance after platinum-based chemotherapy improved progression-free survival in women with newly diagnosed advanced ovarian cancer regardless of BRCA mutation status or homologous recombination status (deficient or proficient). Read Article ›

In the PAOLA-1 study, women with advanced ovarian cancer, regardless of BRCA mutation status, experienced a 40% reduction in the risk for disease progression or death when randomized to olaparib plus bevacizumab compared with placebo and bevacizumab. The reduction in risk with olaparib was greatest in patients whose tumors were homologous recombination deficient. Read Article ›

In a 4-arm randomized study, providing telephone genetic counseling only to those women who have a pathogenic mutation or who request the counseling is noninferior to mandatory pre- and posttest counseling, which may represent a new paradigm for genetic testing. Read Article ›

Selpercatinib Shows Durable Responses in Patients with Thyroid Cancer and RET Mutation
Venclexta plus Azacitidine Improves Overall Survival in Patients with AML
Advances in New Therapies Attributed to Reductions in Lung Cancer Mortality
Read Article ›

Initiating annual breast cancer screening at 40 years of age may reduce mortality rates in women, according to study results published August 12, 2020, in the journal The Lancet Oncology (Duffy SW, et al. Lancet Oncol. 2020;21:1165-1172). Starting earlier screening also did not result in overdiagnosis. Read Article ›

The results of an online questionnaire of 609 breast cancer survivors in the Unites States suggest that almost 50% experienced delays in care during the early weeks of the COVID-19 pandemic. The research was published online on August 9, 2020, in the journal Breast Cancer Research and Treatment (Papautsky EL, et al. Breast Cancer Res Treat. 2020 Aug 9. Epub ahead of print). Read Article ›

In the phase 2 OVARIO study, median progression-free survival has not yet been reached in women with advanced ovarian cancer who are being treated with the combination of niraparib and bevacizumab after response to first-line platinum-based chemotherapy plus bevacizumab. The combination did not appear to cause cumulative toxicities. Read Article ›

An all-oral regimen in women with recurrent platinum-sensitive ovarian cancer did not show superiority to platinum-based regimens on the outcome of progression-free survival. Read Article ›

In a meta-analysis of 7 large randomized clinical trials, PARP inhibitors were not significantly more likely to cause secondary hematologic malignancies compared with control groups. Read Article ›

A pooled analysis of 2 studies using rucaparib for the treatment of patients with recurrent high-grade ovarian cancer supported the approved starting dose of 600 mg twice daily. Read Article ›

A global phase 3 randomized study is currently enrolling patients with stage III or IV high-grade nonmucinous epithelial ovarian cancer to assess the efficacy of an investigational anti–PD-1 humanized monoclonal antibody plus standard of care as first-line treatment and maintenance. The primary outcome measure is progression-free survival. Read Article ›

Page 1 of 12

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: